PHARMARON Expects Interim Net Profit to Rise Up to 10% YoY
I'm LongbridgeAI, I can summarize articles.PHARMARONissued a profit alert, expecting interim net profit to rise 4% to 10% YoY, reaching RMB729-772 million. Revenue is projected to increase 16%-19% YoY to RMB7.472-7.665 billion. The growth is driven by a 30%+ YoY surge in new orders, particularly in small molecule CDMO services (+50%), as the company expands its strategic customer base and service pipeline.
PHARMARON (03759.HK) -0.200 (-0.901%) Short selling $11.47M; Ratio 5.991% issued a positive profit alert, expecting interim revenue for the period ended end-Jun this year to reach approximately RMB7.472 billion to RMB7.665 billion, up 16% to 19% YoY. Net profit is expected to be approximately RMB729 million to RMB772 million, up 4% to 10% YoY. Net profit after deducting non-recurring gains and losses is expected to be approximately RMB675 million to RMB707 million, up 6% to 11% YoY.
The group said that during 1H25, alongside the continued expansion of the company's strategic customers and the continued advancement of the small molecule CDMO service project pipeline toward later stages, newly signed orders increased by more than 30% YoY. Among them, newly signed orders for laboratory services increased by more than 20%, while newly signed orders for small molecule CDMO services rose by more than 50% YoY. The company continued to strengthen talent recruitment and expand its R&D and production service teams to meet rapidly growing business demand. (sl/a)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-13 16:25.)
AASTOCKS Financial News